Erectile Dysfunction Transurethral Therapy
Key points
- Alprostadil, the synthetic formulation of PGE1, is the only pharmacologic agent approved by the FDA for the management of ED via intracavernous and transurethral routes.
- Penile pain is a ubiquitous side effect of alprostadil-based therapies and is clearly dosage-related; in MUSE patients the discomfort can include a dull ache in the penis and the scrotum.
- Clinical trials showed that 66% of men responded to an in-office trial; of these, 65% had successful intercourse at least once at home with MUSE, for a rate of 43% (Padma-Nathan, 1997).
- Alprostadil stimulates adenyl cyclase to increase intracellular levels of cAMP, lowering intracellular concentrations of calcium, thus relaxing arterial and trabecular smooth muscle.
Alprostadil, the synthetic formulation of PGE1, is the only pharmacologic agent approved by the FDA for the management of ED via intracavernous and transurethral routes. Alprostadil stimulates adenyl cyclase to increase intracellular levels of cAMP, lowering intracellular concentrations of calcium, thus relaxing arterial and trabecular smooth muscle. Drug is transferred from urethra to corpus spongiosum to corpus cavernosum. MUSE (medicated urethral system for erection) consists of a very small semisolid pellet (3 × 1 mm) administered into the distal urethra (3 cm) by a proprietary applicator (MUSE VIVUS Inc, Menlo Park, CA).
Clinical trials showed that 66% of men responded to an in-office trial; of these, 65% had successful intercourse at least once at home with MUSE, for a rate of 43% (Padma-Nathan, 1997). With MUSE therapy, the rigidity can be enhanced by an elastic ring placed at the base of the penis (ACTIS, Vivus Inc), to mechanically assist veno-occlusion (Lewis, 1998).
Written and revised by
Andrey Nailor, M.D.
Our doctors write and review articles for accuracy and keep them up to date.
health.am provides general information, not medical advice. Always consult a qualified health professional about your own health.
Explore health topics
More in this topic
Sexual Health →
NewsMayo Clinic study finds younger men with erectile dysfunction at double risk of heart disease
Men who experience erectile dysfunction between the ages of 40 and 49 are twice as likely to develop heart disease than men without dysfunction, according to a new Mayo Clinic study. Researchers also found that men with…
3 February 2009
NewsErectile Dysfunction Treatment May Also Treat Blood Vessel Narrowing in Rheumatic Diseases
When used in addition to other treatments, tadalafil is effective and well tolerated in the treatment of secondary Raynaud’s phenomenon, according to research presented this week at the American College of Rheumatology…
27 October 2008
NewsErectile dysfunction predicts heart problems: study
Problems with maintaining an erection may foretell heart trouble ahead for men with type 2 diabetes, two new studies show. A number of past studies have found a connection between erectile dysfunction (ED) and heart…
